1Department of Internal Medicine, National Cheng Kung University Hospital, Tainan, Taiwan
2Department of pathology, National Cheng Kung University Hospital, Tainan, Taiwan
3Department of Gastroenterology, Kitasato University School of Medicine, Kanagawa, Japan
4Institute of Clinical Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan
Copyright © 2021 Korean Society of Gastrointestinal Endoscopy
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Conflicts of Interest: The authors have no potential conflicts of interest.
Funding
None.
Author Contributions
Conceptualization: Meng-Ying Lin
Data curation: MYL, Cheng-Lin Wu
Formal analysis: MYL
Investigation: MYL, Wei-Lun Chang
Methodology: WLC
Project administration: MYL, WLC
Resources: Bor-Shyang Sheu
Software: MYL
Supervision: BSS, WLC
Validation: Mitsuhiro Kida
Visualization: WLC
Writing-original draft: MYL, CLW
Writing-review&editing: WLC
FNA group (n=30) | FNB group (n=30) | p value | |
---|---|---|---|
Needle size (Oa)/Cb)/Bc)) | <0.001d) | ||
19 G | 7 (1/0/0) | 1 (0/1/0) | |
20 G | 0 | 23 (0/23/0) | |
22 G | 21 (11/7/3) | 6 (0/0/6) | |
25 G | 2 (2/0/0) | 0 | |
The time order of procedure | <0.001 | ||
1–10 | 8 | 2 | |
11–20 | 10 | 0 | |
21–30 | 7 | 3 | |
31–40 | 3 | 7 | |
41–50 | 0 | 10 | |
51–60 | 2 | 8 |
FNA group (n=30) | FNB group (n=30) | p value | |
---|---|---|---|
Age (mean ± SD) | 60.2 ± 11.6 | 62.5 ± 13.8 | 0.427 |
Gender (female: male) | 8: 22 | 12: 18 | 0.273 |
Mass location | 0.231 | ||
Pancreatic UP and head | 11 | 14 | |
Pancreatic body and tail | 13 | 12 | |
Gastric SEML | 3 | 0 | |
Esophagus SEML | 0 | 2 | |
Othersa) | 3 | 2 | |
Mass size | 0.640 | ||
<1 cm | 1 | 1 | |
1–2 cm | 8 | 5 | |
>2 cm | 21 | 24 | |
Final diagnosis | 0.590 | ||
Pancreatic adenocarcinoma | 11 | 13 | |
Pancreatic NET | 4 | 5 | |
Pancreatic benign lesion | 9 | 4 | |
GIST | 1 | 0 | |
Leiomyoma | 1 | 2 | |
Other malignancy | 4 | 5 | |
Other benign | 0 | 1 |
FNA group | FNB group | |
---|---|---|
Total undiagnostic procedure | 10 | 4 |
Atypical cell without stromal invasion | 5 | 0 |
Scant of cell | 2 | 1 |
IHC stain negative | 1 | 1 |
Blood clot | 1 | 1 |
Sampling error | 1 | 1 |
FNA group (n=30) | FNB group (n=30) | p value | |
---|---|---|---|
Needle size (O |
<0.001 |
||
19 G | 7 (1/0/0) | 1 (0/1/0) | |
20 G | 0 | 23 (0/23/0) | |
22 G | 21 (11/7/3) | 6 (0/0/6) | |
25 G | 2 (2/0/0) | 0 | |
The time order of procedure | <0.001 | ||
1–10 | 8 | 2 | |
11–20 | 10 | 0 | |
21–30 | 7 | 3 | |
31–40 | 3 | 7 | |
41–50 | 0 | 10 | |
51–60 | 2 | 8 |
FNA group (n=30) | FNB group (n=30) | p value | |
---|---|---|---|
Age (mean ± SD) | 60.2 ± 11.6 | 62.5 ± 13.8 | 0.427 |
Gender (female: male) | 8: 22 | 12: 18 | 0.273 |
Mass location | 0.231 | ||
Pancreatic UP and head | 11 | 14 | |
Pancreatic body and tail | 13 | 12 | |
Gastric SEML | 3 | 0 | |
Esophagus SEML | 0 | 2 | |
Others |
3 | 2 | |
Mass size | 0.640 | ||
<1 cm | 1 | 1 | |
1–2 cm | 8 | 5 | |
>2 cm | 21 | 24 | |
Final diagnosis | 0.590 | ||
Pancreatic adenocarcinoma | 11 | 13 | |
Pancreatic NET | 4 | 5 | |
Pancreatic benign lesion | 9 | 4 | |
GIST | 1 | 0 | |
Leiomyoma | 1 | 2 | |
Other malignancy | 4 | 5 | |
Other benign | 0 | 1 |
FNA group (n=30) | FNB group (n=30) | p value | |
---|---|---|---|
Number of needle passes | |||
Mean ± SD 1 pass | 2.97 ± 0.49 | 2.43 ± 0.90 | 0.006 |
2 passes | 0 | 5 | 0.013 |
3 passes | 4 | 9 | |
4 passes | 23 | 15 | |
5 passes | 3 | 0 | |
Tissue area (mean ± SD, mm2) | 0.70 ± 1.04 | 2.35 ± 1.75 | <0.001 |
Blood contains | 0.001 | ||
<25% | 1 | 6 | |
25%–50% | 2 | 9 | |
50%–75% | 7 | 9 | |
>75% | 20 | 6 | |
Histology quality | |||
Acceptable | 14/30 (46.7%) | 23/30 (76.7%) | 0.017 |
Inacceptable | 16/30 (53.3%) | 7/30 (23.3%) | |
Histology | |||
Sensitivity (malignancy) | 12/20 (60%) | 21/24 (87.5%) | 0.078 |
Specificity (malignancy) | 10/10 (100%) | 6/6 (100%) | 0.382 |
Accuracy (overall) | 20/30 (66.7%) | 26/30 (86.7%) | 0.125 |
Adverse effect | 1 | 0 | 0.491 |
FNA group | FNB group | |
---|---|---|
Total undiagnostic procedure | 10 | 4 |
Atypical cell without stromal invasion | 5 | 0 |
Scant of cell | 2 | 1 |
IHC stain negative | 1 | 1 |
Blood clot | 1 | 1 |
Sampling error | 1 | 1 |
O: Olympus Medical System, Tokyo; C: Cook endoscopy Inc., Bloomington, IN, USA; B: Boston scientific, Corp., Natick, MA, USA; Comparing the difference in needle size, not company.
Others: mediastinum mass and lymph node FNA, fine needle aspiration; FNB, fine needle biopsy; GIST, Gastrointestinal stromal tumor; NET, Neuroendocrine tumor; SD, standard deviation; SEML, Subepithelial mass lesion; UP, Uncinate process.
FNA, fine needle aspiration; FNB, fine needle biopsy; SD, standard deviation.
FNA, fine needle aspiration; FNB, fine needle biopsy.